Objectives: Coronavirus Disease 2019 (COVID-19) is a rapidly expanding global pandemic resulting in significant morbidity and mortality. COVID-19 patients may present with acute myocardial infarction (AMI). The aim of this study is to conduct detailed analysis on patients with AMI and COVID-19. Methods: We included all patients admitted with AMI and actively known or found to be COVID-19 positive by PCR between the 4 th February 2020 and the 11 th June 2020 in the State of Qatar. Patients were divided into ST-elevation myocardial infarction (STEMI) and Non-STE (NSTEMI). Results: There were 68 patients (67 men and 1 woman) admitted between the 4 th of February 2020 and the 11 th of June 2020 with AMI and COVID-19. The mean age was 49.1±9 years, 46 patients had STEMI and 22 had NSTEMI. 38% had diabetes mellitus, 31% had hypertension, 16% were smokers, 13% had dyslipidemia, and 14.7% had prior cardiovascular disease. Chest pain and dyspnea were the presenting symptoms in 90% and 12% of patients, respectively. Fever (15%) and cough (15%) were the most common COVID-19 symptoms, while the majority had no viral symptoms. Thirty-nine (33 STEMI and 6 NSTEMI) patients underwent coronary angiography, 38 of them had significant coronary disease. In-hospital MACE was low; 1 patient developed stroke and 2 died. Conclusion: Contrary to previous small reports, in-hospital adverse events were low in this largest cohort of COVID-19 patients presenting with AMI. We hypothesize patient’s demographics and profile including younger age contributed to these findings. Further studies are required to confirm this observation. Key questions: What is already known on this subject?: COVID-19 patients may present with acute myocardial infarction (AMI). What might this study add?: Contrary to previous small reports, most COVID-19 patients presenting with AMI have significant obstructive coronary artery disease and favorable in-hospital outcome. How might this impact on clinical practice?: COVID-19 patients presenting with AMI should be treated according to the standard practice.
2 April 2025 in American Heart Journal Plus: Cardiology Research and Practice
Ensuring safety from radiation in catheterization labs is critical due to the cumulative nature of radiation exposure. This study compares the effectiveness of Zero Gravity (ZG) and conventional Lead Apron shields in coronary angiography and percutaneous coronary intervention. Over six months, radiation exposure was assessed for two operators performing angiography procedures. One operator used a Lead Apron, while the other used the Zero Gravity system. Radiation was measured using Thermoluminescent Dosimeters (TLDs). Procedural characteristics, fluoroscopy time, and contrast dose were recorded. Feedback on Lead Apron use was collected using the Oswestry Low Back Pain Disability Questionnaire. Each operator performed 63 procedures with similar characteristics. Zero Gravity showed no significant difference in whole-body radiation exposure (De) compared to the Lead Apron (0.349 mSv vs. 0.346 mSv). However, Zero Gravity resulted in a lower external skin dose (Ds) compared to the Lead Apron (0.314 mSv vs. 0.339 mSv). Most cardiologists reported minimal disability from using Lead Aprons. Zero Gravity and Lead Apron provide comparable whole-body radiation protection, with Zero Gravity slightly reducing skin exposure. While ZG does not significantly alter overall radiation exposure, it may reduce ergonomic issues associated with Lead Aprons. Zero Gravity provides comparable whole-body radiation protection to Lead Aprons and reduces skin exposure. Further research is needed to address long-term impacts and enhance protective strategies in catheterization labs.